{
    "nct_id": "NCT03063762",
    "official_title": "An Open-Label, Multi-Center, Randomized, Dose-Escalation, Phase 1b Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 in Combination With Atezolizumab ± Bevacizumab in Patients With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Symptomatic or untreated central nervous system (CNS) metastases\n* Participants with asymptomatic CNS metastases with previous or concomitant brain deficiencies, as defined in the protocol\n* Participants with confirmed bilateral pleural effusion\n* Episode of significant cardiovascular/cerebrovascular acute disease within 6 months prior to Cycle 1 Day 1\n* Active or uncontrolled infections\n* Human immunodeficiency virus (HIV) or active Hepatitis A, B, C, D and E virus (HAV, HBV, HCV, HDV and HEV) infection.\n* Major surgery or significant traumatic injury <28 days prior to Cycle 1 Day 1 (excluding fine needle biopsies) or anticipation of the need for major surgery during study treatment\n* Serious, non-healing wound; active ulcer; or untreated bone fracture\n* Proteinuria as demonstrated by a urine protein to creatinine ratio (UPCR) of >=1.0 at screening\n* History of, active or suspicion of autoimmune disease\n* Concurrent use of high dose of systemic steroids. The use of inhaled, topical and ophthalmic steroids is allowed.",
    "miscellaneous_criteria": "Inclusion criteria:\n\n* Unresectable advanced and/or metastatic RCC with component of clear cell histology and/or component of sarcomatoid histology that has not been previously treated with any systemic therapy, including treatment in the adjuvant setting\n* During dose escalation only, an additional population with unresectable advanced and/or metastatic 2nd line RCC patients is allowed\n* At least one tumor lesion with location accessible to biopsy per clinical judgment of the treating physician\n* Consent to provide an archival tumor tissue sample (if available) and to undergo baseline and on treatment tumor biopsies for pharmacodynamic biomarker analysis\n* Measurable disease, as defined by RECIST v1.1. At least one lesion accessible for biopsy\n* Participants with unilateral pleural effusion are eligible if they fulfill both of the following: (a) New York Heart Association (NYHA) Class 1; (b) Global initiative for obstructive lung disease (GOLD) test level 1 (forced expiratory volume in 1 second [FEV1]/ forced vital capacity [FVC] less than [<] 0.7 and FEV1 greater than or equal to [>=] 80 percent [%] predicted after inhaled bronchodilator)\n\nAdequate hematological function: neutrophil count of ≥1.5 ≥109 cells/L, platelet count of ≥100,000/≥L, Hb ≥9 g/dL (5.6 mmol/L), lymphocytes ≥0.8 ≥109 cells/L."
}